Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Researchers focus on parrots, poultry and phage therapy
2014-10-10

Photo: en.wikipedia

Veterinary biotechnology focuses on microbial and molecular biological approaches to veterinary illnesses. The group working on veterinary biotechnology research at the University of the Free State (UFS) consists of two academic staff members, Prof Rob Bragg and Dr Charlotte Boucher, two post-doctoral fellows, Drs Chris Theron and Arina Hitzeroth, five PhD and three honours students.

The group has three research focus areas.

Dr Boucher says, “Our main focus area is infectious coryza in poultry, caused by the bacterium Avibacterium paragalliarum. The aim is the control of the disease, mainly through improvement of vaccines, understanding the immune response and improved biosecurity. A key objective is improving methods for serotyping; studying of selected surface antigens and investigating the influence recently discovered bacteriophages might have on virulence. We have co-operative projects with research groups in China, India and Israel.

“The second focus area is an expression system co-developed with the National Institute for Agronomic Research (INRA), France. The flagship project is the expression of the coat protein gene of the beak and feather disease virus, a disease affecting parrots, currently threatening the endangered Cape parrot. This system has led to the development of serological tests, currently under patenting. The application of this system has been extended to human-related diseases, with two interdisciplinary projects underway, co-working with Profs Muriel Meiring and Felicity Burt. Prof Meiring is working on diseases causing bleeding disorders, such as blood-clotting impairment, while Prof Burt is working on viral infections causing haemorrhagic (bleeding) disorders.

“We are also researching disease control in a post-antibiotic era, investigating the potential of phage-therapy by targeting and destroying pathogenic islands within a host, with reduced side-effects on the host itself.

“We have smaller projects, including an interdisciplinary project with Zoology, looking at the protein profile of amphibian (frog) secretions with the focus on antimicrobial activity, as these secretions assist with protecting amphibian skin against infections.”  


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept